Embla Wants Employers to Buy Less GLP-1 - and Better Weight Care

The Danish-founded health company built a weight-care business around an unfashionable proposition: the expensive drug should be a temporary tool, not the entire product. Its next test is whether a 2,694-person real-world study can persuade American benefits buyers.